|
1
|
Ferlay J, Bray F, Parkin DM and Pisani P:
Gobocan 2000: Cancer incidence and mortality worldwide (IARC Cancer
Bases No. 5). Lyon: IARC Press; 2001
|
|
2
|
Lau M, Le A and El-Serag HB: Noncardia
gastric adenocarcinoma remains an important and deadly cancer in
the United States: Secular trends in incidence and survival. Am J
Gastroenterol. 101:2485–2492. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nashimoto A, Akazawa K, Isobe Y, Miyashiro
I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, et
al: Gastric cancer treated in 2002 in Japan: 2009 annual report of
the JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boku N, Yamamoto S, Fukuda H, Shirao K,
Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et
al: Fluorouracil versus combination of irinotecan plus cisplatin
versus S-1 in metastatic gastric cancer: A randomised phase 3
study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamaguchi K, Sawaki A, Doi T, Satoh T,
Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, et al:
Efficacy and safety of capecitabine plus cisplatin in Japanese
patients with advanced or metastatic gastric cancer: Subset
analyses of the AVAGAST study and the ToGA study. Gastric Cancer.
16:175–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koizumi W, Nakayama N, Tanabe S, Sasaki T,
Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, et al: A
multicenter phase II study of combined chemotherapy with docetaxel,
cisplatin and S-1 in patients with unresectable or recurrent
gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 69:407–413.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okines AF, Norman AR, McCloud P, Kang YK
and Cunningham D: Meta-analysis of the REAL-2 and ML17032 trials:
Evaluating capecitabine-based combination chemotherapy and infused
5-fluorouracil-based combination chemotherapy for the treatment of
advanced oesophago-gastric cancer. Ann Oncol. 20:1529–1534. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamaguchi T, Shirao K, Ohtsu A, Hyodo I,
Arai Y, Takiuchi H, Fujii H, Yoshida M, Saito H, Denda T, et al: A
phase II study of biweekly mitomycin C and irinotecan combination
therapy in patients with fluoropyrimidine-resistant advanced
gastric cancer: A report from the Gastrointestinal oncology group
of the Japan clinical oncology group (JCOG0109-DI Trial). Gastric
Cancer. 14:226–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kodera Y, Ishiyama A, Yoshikawa T,
Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A,
Sakamoto J, et al: A feasibility study of postoperative
chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma
(CCOG0703). Gastric Cancer. 13:197–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuburaya A, Nagata N, Cho H, Hirabayashi
N, Kobayashi M, Kojima H, Munakata Y, Fukushima R, Kameda Y,
Shimoda T, et al: Phase II trial of paclitaxel and cisplatin as
neoadjuvant chemotherapy for locally advanced gastric cancer.
Cancer Chemother Pharmacol. 71:1309–1314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirakawa M, Sato Y, Ohnuma H, Takayama T,
Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, et
al: A phase II study of neoadjuvant combination chemotherapy with
docetaxel, cisplatin, and S-1 for locally advanced resectable
gastric cancer: Nucleotide excision repair (NER) as potential
chemoresistance marker. Cancer Chemother Pharmacol. 71:789–797.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshikawa T, Rino Y, Yukawa N, Oshima T,
Tsuburaya A and Masuda M: Neoadjuvant chemotherapy for gastric
cancer in Japan: A standing position by comparing with adjuvant
chemotherapy. Surg Today. 44:11–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ott K, Weber WA, Lordick F, Becker K,
Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M and Siewert JR:
Metabolic imaging predicts response, survival, and recurrence in
adenocarcinomas of the esophagogastric junction. J Clin Oncol.
24:4692–46988. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weber WA, Ott K, Becker K, Dittler HJ,
Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR,
Schwaiger M and Fink U: Prediction of response to preoperative
chemotherapy in adenocarcinomas of the esophagogastric junction by
metabolic imaging. J Clin Oncol. 19:3058–3065. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lordick F, Ott K, Krause BJ, Weber WA,
Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K,
et al: PET to assess early metabolic response and to guide
treatment of adenocarcinoma of the oesophagogastric junction: The
MUNICON phase II trial. Lancet Oncol. 8:797–805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurokawa Y, Shibata T, Sasako M, Sano T,
Tsuburaya A, Iwasaki Y and Fukuda H: Validity of response
assessment criteria in neoadjuvant chemotherapy for gastric cancer
(JCOG0507-A). Gastric Cancer. 17:514–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Becker K, Mueller JD, Schulmacher C, Ott
K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H:
Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heger U, Bader F, Lordick F, Burian M,
Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, et
al: Interim endoscopy results during neoadjuvant therapy for
gastric cancer correlate with histopathological response and
prognosis. Gastric Cancer. 17:478–488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ott K, Fink U, Becker K, Stahl A, Dittler
HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, et al:
Prediction of response to preoperative chemotherapy in gastric
carcinoma by metabolic imaging: Results of a prospective trial. J
Clin Oncol. 21:4604–4610. 2003. View Article : Google Scholar : PubMed/NCBI
|
